Previous 10 | Next 10 |
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic fibrosis (CF) lung disease in people with CF (pwCF) who are ineligible for or cannot tolerate a...
Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling advancement into Phase 3 pivotal development, with initiation expected in Q1 2025 Positiv...
2024-02-20 05:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-19 20:42:02 ET Summary Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness, with wet AMD being a more severe form. Current treatment for wet AMD involves frequent anti-VEGF injections, but there is a need for therapies with less frequent ...
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO 2 (cardiopulmonary exercise testing) and/or cardiac quality of life (KCCQ) in all five evaluable patients Cardiac biopsies were obtained fr...
2024-02-11 04:27:27 ET Summary Ocular Therapeutix is using its Elutyx technology to develop drug candidates for eye disorders, with upcoming results from the HELIOS study for diabetic retinopathy Q2 2024. The company is also progressing with the phase 3 SOL study for wet age-relat...
2024-02-09 08:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-08 18:40:34 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 4D Molecular Therapeutics up 3%, prices $300M equity Biggest sto...
2024-02-07 05:50:15 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 4D Molecular stock jumps after positive interim data for eye disease dru...
2024-02-06 14:00:09 ET Kostas Biliouris from BMO Capital issued a price target of $70.00 for FDMT on 2024-02-06 14:05:00. The adjusted price target was set to $70.00. At the time of the announcement, FDMT was trading at $30.705. The overall price target consensus is at $...
News, Short Squeeze, Breakout and More Instantly...
4D Molecular Therapeutics Inc. Company Name:
FDMT Stock Symbol:
NASDAQ Market:
Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3 expected by Q1 2025 Interim 24-week landmark analysis from PRISM Phase 2 Population Ext...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that manage...